Amplifon doubles Q2 sales and upgrades 2021 guidance

In Q2, hearing aid seller Amplifon made significant progress on multiple markets, leading the Italian company to raise its guidance for all of 2021.

BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN

Published: 30.07.21 at 10:13

The covid-19 crisis seems to have loosened its grip on the hearing aid industry, which was heavily affected by the virus last year.

Italian hearing aid seller Amplifon, which is a client of both Demant and GN Hearing, has had the wind in its sails during Q2 this year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

More from MedWatch

Former Ambu CEO's equity investments end in USD 2m losses

Juan Jose Gonzalez, who was the CEO of medtech firm Ambu until very recently, has lost just over DKK 16m (USD 2.3m) before taxes on his share purchases.

Jesper Høiland retires as chief commercial officer of Ascendis Pharma

Jesper Høiland, outgoing global chief commercial officer of Ascendis Pharma | Foto: Radius Health / PR

Former executive vice president of Novo Nordisk, US, Jesper Høiland has decided to step down from his role as global chief commercial officer at Ascendis Pharma.

ALK finds replacement for long-time North America lead

Nearly 23 years as head of the US at ALK have come to end for Jorge Alderete, who is retiring effective June 30 | Foto: ALK / PR

Jorge Alderete, ALK’s president in North America, is leaving the firm after 23 years. He will be replaced by Hans Lindeberg, ALK’s current head of the Nordic region.

Monkeypox vaccine attracts interest for Bavarian as virus spreads

Foto: Bavarian Nordic / PR

Bavarian, which signed a supply contract with an unnamed European country last week, reports it is in dialog with several countries, some yet to be affected, concerning the firm’s monkeypox vaccine.

Almirall announces Danish launch of MC2 Therapeutics-developed psoriasis cream

Foto: Mikkel Aabenhus Hemmingsen / MedWatch

Almirall is launching psoriasis cream Wynzora in Denmark. The treatment has been inlicensed from Danish firm MC2 Therapeutics, where the CEO says ”it is a special feeling” to see Wynzora launched in its home country.

Further reading

Related articles